Si-Han Liu

PGG Potentiates Olaparib-Induced DNA Damage and STING-Associated Immunogenic Signaling to Enhance PD-L1 Blockade in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is a highly aggressive malignancy and options for targeted therapy are limited. Although PARP inhibitors (PARPi) like olaparib (Ola) leverage synthetic lethality, their clinical utility is severely impeded by drug resistance and low frequency of BRCA mutations. In this study, 1,2,3,...